GlassScriptPhysician profile
Julia S Billington
NPI 1104873801
$619.85
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $210 · 2021: $13.41.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $113.75 | 2019-2020 | |
| Pfizer INC. | $109.35 | 2019-2020 | |
| Allergan, INC. | $79.54 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.23 | 2019-2020 | |
| Lilly USA, LLC | $43.13 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $30.39 | 2020 | |
| Therapeuticsmd, INC. | $24.58 | 2019 | |
| Sunovion Pharmaceuticals INC. | $22.84 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.39 | 2019 | |
| Mannkind Corporation | $18.93 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.88 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $15.12 | 2019 | |
| Abbvie INC. | $13.41 | 2021 | |
| Amgen INC. | $12.03 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.88 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $11.74 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.66 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Billington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.